Ligelizumab

Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC) . Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) [1][2].

Product Specifications

CAS Number

[1322627-61-1]

Product Name Alternative

QGE 031; Anti-IGHE Recombinant Antibody

UNSPSC

12352203

Target

Fc Receptor (FcR)

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ligelizumab.html

Purity

99.85

Solubility

H2O

Smiles

[Ligelizumab]

Molecular Weight

(146.32 kDa)

References & Citations

[1]Gasser P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020 Jan 8;11 (1) :165.|[2]Benito-Villalvilla C, et al. Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3+ Treg generation. Allergy. 2023 Apr;78 (4) :1060-1072.